AIDS

1. WANG L, Moqueet N, Simkin A, Knight J, et al
   Mathematical modelling of the influence of serosorting on the population-level HIV transmission impact of pre-exposure prophylaxis.
   AIDS. 2021 Jan 29. pii: 00002030-900000000-96503.
   

   >> Share

   
   
2. MADEDDU G, De Vito A, Cozzi-Lepri A, Cingolani A, et al
   Time spent with viral load
   AIDS. 2021 Jan 29. pii: 00002030-900000000-96502.
   

   >> Share

   
   
3. OLIVEIRA NL, Kennedy EH, Tibshirani R, Levine A, et al
   Longitudinal 5-year prediction of cognitive impairment among men with HIV disease.
   AIDS. 2021 Jan 29. pii: 00002030-900000000-96501.
   

   >> Share

   
   
4. MUCCINI C, Galli L, Poli A, Godino C, et al
   Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY.
   AIDS. 2021 Jan 29. pii: 00002030-900000000-96500.
   

   >> Share

   
   
5. GEBREBRHAN H, Kambaran C, Sivro A, Adhiambo W, et al
   Rectal microbiota diversity in Kenyan men who have sex with men (MSM) is inversely associated with frequency of receptive anal sex, independent of HIV status.
   AIDS. 2021 Jan 29. pii: 00002030-900000000-96499.
   

   >> Share

   
   
6. CHAN P, Kerr SJ, Kroon E, Colby D, et al
   Cognitive trajectories after treatment in acute HIV infection.
   AIDS. 2021 Jan 29. pii: 00002030-900000000-96498.
   

   >> Share

   
   

   
   Am J Epidemiol

7. VANOBBERGHEN F, Weisser M, Kasuga B, Katende A, et al
   Mortality Rate in a Cohort of People Living With HIV in Rural Tanzania After Accounting for Unseen Deaths Among Those Lost to Follow-up.
   Am J Epidemiol. 2021;190:251-264.
   

   >> Share

   
   
8. MCMANUS H, Callander D, Asselin J, McMahon J, et al
   A New Method for Estimating the Incidence of Infectious Diseases.
   Am J Epidemiol. 2021 Feb 4. pii: 6127136. doi: 10.1093.
   

   >> Share

   
   

   
   Antimicrob Agents Chemother

9. MANDAL S, Prathipati PK, Sunagawa SW, Destache CJ, et al
   A new combination bictegravir+tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 PrEP: A concept evaluation study.
   Antimicrob Agents Chemother. 2021 Feb 1. pii: AAC.02320.
   

   >> Share

   
   

   
   Clin Infect Dis

10. PEEL J, Chow EPF, Denham I, Schmidt T, et al
    Clinical presentation of incident syphilis among men who have sex with men taking HIV Pre-Exposure Prophylaxis in Melbourne, Australia.
    Clin Infect Dis. 2021 Feb 1. pii: 6125283. doi: 10.1093.
    

    >> Share

    
    
11. SIEGLER AJ
    Needed: A Life Course Perspective on Maintaining Pre-exposure Prophylaxis Use.
    Clin Infect Dis. 2021;72:386-387.
    

    >> Share

    
    
12. HUANG YA, Tao G, Smith DK, Hoover KW, et al
    Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012-2017.
    Clin Infect Dis. 2021;72:379-385.
    

    >> Share

    
    
13. RAUGI DN, Ba S, Cisse O, Diallo K, et al
    Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.
    Clin Infect Dis. 2021;72:369-378.
    

    >> Share

    
    
14. PAPASAVVAS E, Azzoni L, Ross BN, Fair M, et al
    Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy.
    Clin Infect Dis. 2021;72:495-498.
    

    >> Share

    
    
15. STALTER RM, Baeten JM, Donnell D, Spinelli MA, et al
    Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.
    Clin Infect Dis. 2021;72:486-489.
    

    >> Share

    
    
16. RUFFIEUX Y, Muchengeti M, Egger M, Efthimiou O, et al
    Immunodeficiency and Cancer in 3.5 Million People Living with Human Immunodeficiency Virus: the South African HIV Cancer Match Study.
    Clin Infect Dis. 2021 Feb 2. pii: 6126767. doi: 10.1093.
    

    >> Share

    
    
17. PEPPERRELL T, Venter WDF, McCann K, Bosch B, et al
    Participants on dolutegravir re-suppress HIV RNA after virologic failure: updated data from the ADVANCE trial.
    Clin Infect Dis. 2021 Feb 2. pii: 6126766. doi: 10.1093.
    

    >> Share

    
    
18. WOLTER N, Cohen C, Tempia S, Walaza S, et al
    Epidemiology of pertussis in individuals of all ages hospitalised with respiratory illness in South Africa, January 2013 - December 2018.
    Clin Infect Dis. 2021 Feb 2. pii: 6126768. doi: 10.1093.
    

    >> Share

    
    
19. DU PREEZ K, Osman M, Seddon JA, Naidoo P, et al
    The impact of the evolving HIV response on the epidemiology of tuberculosis in South African children and adolescents.
    Clin Infect Dis. 2021 Feb 3. pii: 6127007. doi: 10.1093.
    

    >> Share

    
    

    
    HIV Med

20. PUNEKAR YS, Parks D, Joshi M, Kaur S, et al
    Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13050.
    

    >> Share

    
    
21. CROXFORD S, Burns F, Copas A, Yin Z, et al
    Trends and predictors of linkage to HIV outpatient care following diagnosis in the era of expanded testing in England, Wales and Northern Ireland: Results of a national cohort study.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13078.
    

    >> Share

    
    
22. YANAVICH C, Pacheco AG, Cardoso SW, Nunes EP, et al
    Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13060.
    

    >> Share

    
    

    
    Int J Dermatol

23. ABADIAS-GRANADO I, Navarro-Bielsa A, Ferrando-Lamana L, Requena-Calleja MA, et al
    Hyperpigmentation as a guiding sign for the diagnosis of visceral leishmaniasis in a patient with human immunodeficiency virus (HIV).
    Int J Dermatol. 2021 Feb 1. doi: 10.1111/ijd.15429.
    

    >> Share

    
    

    
    J Acquir Immune Defic Syndr

24. PAGKAS-BATHER J, Khosropour CM, Golden MR, Thibault C, et al
    Population-level Effectiveness of HIV pre-exposure prophylaxis among MSM and Transgender Persons with Bacterial Sexually Transmitted Infections.
    J Acquir Immune Defic Syndr. 2021 Feb 2. pii: 00126334-900000000-95949.
    

    >> Share

    
    
25. SHARMA A, Hoover DR, Shi Q, Gustafson DR, et al
    High Frequency of Recurrent Falls among Pre-frail and Frail Women with and without HIV.
    J Acquir Immune Defic Syndr. 2021 Feb 2. pii: 00126334-900000000-95950.
    

    >> Share

    
    
26. SABERI P, Ming K, Hojilla JC, Scott HM, et al
    HIV pre-exposure prophylaxis in the time of COVID-19: How a robust and responsive HIV PrEP intervention can avert loss of HIV prevention coverage during a global pandemic.
    J Acquir Immune Defic Syndr. 2021 Jan 29. pii: 00126334-900000000-95952.
    

    >> Share

    
    
27. WAIRIMU F, Ward NC, Liu Y, Dwivedi G, et al
    Cardiac transplantation in HIV positive patients: a narrative review.
    J Acquir Immune Defic Syndr. 2021 Jan 29. pii: 00126334-900000000-95951.
    

    >> Share

    
    

    
    J Clin Invest

28. MATSUDA K, Migueles SA, Huang J, Bolkhovitinov L, et al
    A replication competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.
    J Clin Invest. 2021 Feb 2. pii: 140794. doi: 10.1172/JCI140794.
    

    >> Share

    
    

    
    J Infect Dis

29. PARK SY, Faraci G, Murphy G, Pilcher C, et al
    Microdrop HIV sequencing for incidence and drug resistance surveillance.
    J Infect Dis. 2021 Jan 31. pii: 6124747. doi: 10.1093.
    

    >> Share

    
    

    
    J Virol

30. ARACHCHIGE SP, Henke W, Kalamvoki M, Stephens EB, et al
    Structural Domains of the Herpes Simplex Type 1 gD Protein that Restrict HIV-1 Particle Infectivity.
    J Virol. 2021 Feb 3. pii: JVI.02355-20. doi: 10.1128/JVI.02355.
    

    >> Share

    
    
31. GRAMATICA A, Schwarzer R, Brantley W, Varco-Merth B, et al
    Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo.
    J Virol. 2021 Feb 3. pii: JVI.02393-20. doi: 10.1128/JVI.02393.
    

    >> Share

    
    
32. PILKINTON MA, McDonnell WJ, Barnett L, Chopra A, et al
    In chronic infection, HIV gag-specific CD4+ T cell receptor diversity is higher than CD8+ T cell receptor diversity and is associated with less HIV quasispecies diversity.
    J Virol. 2021 Feb 3. pii: JVI.02380-20. doi: 10.1128/JVI.02380.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

33. TSONDAI PR, Davies MA, Singtoroj T, Maxwell N, et al
    Improving Methods to Classify Perinatal versus Nonperinatal HIV Acquisition in Young Adolescents 10-14 Years of Age.
    Pediatr Infect Dis J. 2021 Feb 1. pii: 00006454-900000000-95880.
    

    >> Share

    
    

    
    Pediatrics

34. KONERU A, Fenlon N, Schillie S, Williams C, et al
    National Perinatal Hepatitis B Prevention Program: 2009-2017.
    Pediatrics. 2021 Feb 2. pii: peds.2020-1823. doi: 10.1542/peds.2020-1823.
    

    >> Share

    
    

    
    PLoS Comput Biol

35. DEARLOVE B, Tovanabutra S, Owen CL, Lewitus E, et al
    Factors influencing estimates of HIV-1 infection timing using BEAST.
    PLoS Comput Biol. 2021;17:e1008537.
    

    >> Share

    
    

    
    PLoS Med

36. POLITCH JA, Cu-Uvin S, Moench TR, Tashima KT, et al
    Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial.
    PLoS Med. 2021;18:e1003495.
    

    >> Share

    
    

    
    PLoS One

37. DE MENDONCA EB, Schmaltz CA, Sant'Anna FM, Vizzoni AG, et al
    Anemia in tuberculosis cases: A biomarker of severity?
    PLoS One. 2021;16:e0245458.
    

    >> Share

    
    
38. PARKER B, Ward T, Hayward O, Jacob I, et al
    Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
    PLoS One. 2021;16:e0245955.
    

    >> Share

    
    
39. KHAN MS, Rego S, Rajal JB, Bond V, et al
    Mitigating the impact of COVID-19 on tuberculosis and HIV services: A cross-sectional survey of 669 health professionals in 64 low and middle-income countries.
    PLoS One. 2021;16:e0244936.
    

    >> Share

    
    
40. ROOZEN GVT, Meel R, Peper J, Venter WDF, et al
    Electrocardiographic and echocardiographic abnormalities in urban African people living with HIV in South Africa.
    PLoS One. 2021;16:e0244742.
    

    >> Share

    
    
41. ADEDINI SA, Mobolaji JW, Alabi M, Fatusi AO, et al
    Changes in contraceptive and sexual behaviours among unmarried young people in Nigeria: Evidence from nationally representative surveys.
    PLoS One. 2021;16:e0246309.
    

    >> Share

    
    
42. GBEASOR-KOMLANVI FA, Zida-Compaore WIC, Sadio AJ, Tchankoni MK, et al
    HIV testing uptake and prevalence among hospitalized older adults in Togo: A cross-sectional study.
    PLoS One. 2021;16:e0246151.
    

    >> Share

    
    
43. HIDALGO-TENORIO C, Garcia-Martinez CM, Pasquau J, Omar-Mohamed-Balgahata M, et al
    Risk factors for >/=high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments.
    PLoS One. 2021;16:e0245870.
    

    >> Share

    
    
44. AYERDI AGUIRREBENGOA O, Vera Garcia M, Arias Ramirez D, Gil Garcia N, et al
    Low use of condom and high STI incidence among men who have sex with men in PrEP programs.
    PLoS One. 2021;16:e0245925.
    

    >> Share

    
    
45. LIM RK, Semitala FC, Atuhumuza E, Sabiti L, et al
    Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda.
    PLoS One. 2021;16:e0246113.
    

    >> Share

    
    
46. CARTER G, Woodward B, Ohmit A, Gleissner A, et al
    Primary care providers as a critical access point to HIV information and services for African American and Latinx communities.
    PLoS One. 2021;16:e0246016.
    

    >> Share

    
    
47. FISEHA T, Ahmed E, Chalie S, Gebreweld A, et al
    Prevalence and associated factors of impaired renal function and albuminuria among adult patients admitted to a hospital in Northeast Ethiopia.
    PLoS One. 2021;16:e0246509.
    

    >> Share

    
    
48. TYRBERG E, Eden A, Eriksen J, Nilsson S, et al
    Higher plasma drug levels in elderly people living with HIV treated with darunavir.
    PLoS One. 2021;16:e0246171.
    

    >> Share

    
    
49. KIYAGA C, Narayan V, McConnell I, Elyanu P, et al
    Uganda's "EID Systems Strengthening" model produces significant gains in testing, linkage, and retention of HIV-exposed and infected infants: An impact evaluation.
    PLoS One. 2021;16:e0246546.
    

    >> Share

    
    
50. KUSEMERERWA S, Akena D, Nakanjako D, Kigozi J, et al
    Strategies for retention of heterosexual men in HIV care in sub-Saharan Africa: A systematic review.
    PLoS One. 2021;16:e0246471.
    

    >> Share

    
    
51. KIM TO, Lee JK, Kwon YS, Kim YI, et al
    Clinical characteristics and prognosis of patients with Pneumocystis jirovecii pneumonia without a compromised illness.
    PLoS One. 2021;16:e0246296.
    

    >> Share

    
    

    
    PLoS Pathog

52. RENNER N, Mallery DL, Faysal KMR, Peng W, et al
    A lysine ring in HIV capsid pores coordinates IP6 to drive mature capsid assembly.
    PLoS Pathog. 2021;17:e1009164.
    

    >> Share

    
    
53. DINKELE R, Gessner S, McKerry A, Leonard B, et al
    Capture and visualization of live Mycobacterium tuberculosis bacilli from tuberculosis patient bioaerosols.
    PLoS Pathog. 2021;17:e1009262.
    

    >> Share

    
    

    
    Vaccine

54. SEREMBA E, Ocama P, Ssekitoleko R, Mayanja-Kizza H, et al
    Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda.
    Vaccine. 2021 Jan 27. pii: S0264-410X(21)00070.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share